Spectrum Pharmaceuticals announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021.